Dietary Restriction to Prevent Cardiotoxicity in Breast Cancer Patients

Launched by ERASMUS MEDICAL CENTER · Sep 30, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how a special diet may help prevent heart problems in women with early breast cancer who are receiving a specific type of chemotherapy called anthracycline. The researchers want to see if a short-term diet that reduces calories by 30% and increases protein intake can make a difference in heart health, as measured by a blood test that checks for a certain protein related to heart damage.

To join the study, participants need to be women aged 18 to 75 who have recently been diagnosed with triple negative breast cancer and are about to start chemotherapy. They should have a body mass index (BMI) of at least 19 and must not have any serious heart issues or allergies to the diet's ingredients. Participants will be divided into two groups: one will follow the special diet while the other will continue with their regular eating habits. The trial is currently recruiting, and taking part may help researchers find better ways to protect heart health during cancer treatment.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • women with newly diagnosed triple negative breast cancer with an indication for (neo-)adjuvant ATC-based chemotherapy and of intent to start anticancer treatment;
• • age between 18 and 75 years;
• • written informed consent;
• • body mass index ≥ 19.
• Exclusion Criteria:
• • Allergic to any of the ingredients of the diet;
• • Known history of cardiac dysfunction;
• • Severe morbidity with the inability to receive anticancer treatment.
• • Participation in another clinical trial with an intervention arm (database and/or biobank studies excluded);
• • Pregnant women
• • Previous treatment with anthracycline
• • Estrogen receptor positive status